NorwayNorway

Euro2 Million for Nordic Centres

10.07.2004

Oslo/Lund/Helsinki - Three Nordic networks have been recently granted financial support from the joint Nordic venture “Nordic Centre of Excellence Programme in Molecular Medicine” to explore Parkinson's, Alzheimer's, stroke, migraine, epilepsy, cancer and auto-immune and metabolic disorders. During 2004 to 2009, the three centres of excellence from Norway, Sweden, and Finland will receive Euro2 million each. The funding will mainly be used for promoting researcher mobility, education, and exchange between research teams. The three Nordic Centres of Excellence (NcoEs) granted funding were the:
- Nordic Centre of Excellence for Research in Water Imbalance Related Disorders (Prof. Ole Petter Ottersen, Oslo Univer- sity),
- NcoE in Neurodegeneration (Prof. Patrik Brundin, Lund University) and
- Nordic Network of Excellence in Disease Genetics (Prof. Leena Peltonen, Univer- sity of Helsinki).
The initiators and financiers of the programme are the joint committee of the Nordic Medical Research Council, the Nordic Council of Ministers, and the Nordic Academy for Advanced Study.

NorwayNorway

05.04.2011

Oslo – Norwegian Algeta ASA has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform Under the terms of the agreement, Genzyme will provide access to a novel tumour-targeting antibody,...

NorwayNorway

05.04.2011

Trondheim – Norway-based APIM Therapeutics AS has received a follow-up investment from Sarsia Seed, one of its previous investors. APIM focusses on novel drug candidates that potentiate the action of current chemo­therapeutics to...

NorwayNorway

04.11.2010

Oslo – Norwegian diagnostic specialist DiaGenic ASA has raised NOK70m (EUR 8.5m) through the sale of 140 million shares at NOK0.50 per share in a private placement to new and existing investors. DnB NOR Markets acted as manager...

NorwayNorway

03.11.2010

Oslo – The Oslo Cancer Cluster and the Shanghai Institute of Materia Medica (SIMM), have signed a memorandum of understanding aimed at accelerating the development and adoption of new cancer therapies. Overall, the collaboration...

NorwayNorway

18.09.2010

Oslo/Berlin – Algeta is cashing in on its lead product Alpharadin, a targeted alpha-radiopharmaceutical in clinical trials for treating bone metastases in cancer patients. Bayer Schering Pharma has agreed to pay the Norwegian...

NorwayNorway

11.07.2010

Lysaker – Norwegian biopharmaceutical company PCI Biotech Holding ASA has strengthened the company’s equity by a11m (NOK90m) through a share issue of 2.25 million shares with preemptive subscription rights for existing...

Displaying results 11 to 20 out of 92

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/1/article/euro2-million-for-nordic-centres.html

Product of the week

Products

Events

All Events

Current issue

All issues